Hitachi showcases cardiac PET

TriMed Staff | | Health Imaging | Cardiac Imaging

Hitachi Medical Systems America Inc. (HMSA) highlighted this week at the annual Society of Nuclear Medicine (SNM) meeting in San Diego its cardiac PET system – the SceptreC. The system is configured for cardiac PET to allow the utilization of both Rubidium-82 for myocardial perfusion and 18-FDG for myocardial viability procedures, the company said.

"Whole-body PET/CT offers significant throughput advantages for oncology," said Raymond Wtulich, PET & PET/CT product manager. "However, in cardiac imaging only one bed position is required for a stress or rest acquisition making dedicated PET a comparable throughput solution at a dramatically lower cost for both equipment and service."

The SceptreC’s fast acquisition provides an efficient assessment of both stress and rest myocardial perfusion in less than 40 minutes. The system also is optimized with 3D Pico electronics to provide high-count rate capability and includes the Emory Cardiac Software PETtools for cardiac quantification to deliver an alternative solution to SPECT or PET/CT for myocardial perfusion and viability studies, Hitachi said.

TriMed Staff

Related Content

Global shortage of nuclear imaging isotopes may be over
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
FDA clears AI tool that flags signs of heart disease in chest CT scans
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients
Abbott CGM sensors can now be worn during common imaging procedures
New data highlight long-term benefits of HeartFlow’s AI-based CAD evaluations

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup